Citations

Clear

949 citation(s) found for "Li, Bryan".

Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Pluvinage, John V. , Ngo, Thomas , Fouassier, Camille , McDonagh, Maura A. , Holmes, Brandon B. , Bartley, Christopher M. , Kondapavulur, Sravani , Hurabielle, Charlotte , Bodansky, Aaron , Pai, Vincent , Aslanpour, Ava , Alvarenga, Bonny D. , Zamecnik, Colin R. , Asencor, Andoni I., Huynh, Thanh Dat , Browne, Weston, Tubati, Asritha , Haney, Michael S. , Douglas, Vanja C. , Louiné, Martineau , Hauser, Stephen L. , Baranzini, Sergio E. , Wells, James A. , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth , Gillum, Leslie A. , Hales, Chadwick M. , Anderson, Mark S. , Smith, Bryan , Nath, Avindra , Green, Ari , Wilson, Michael R. , McDonagh, Maura , Hinman, Sam , Alvarenga, Bonny D , Zorn, Kelsey C , Zamecnik, Colin , Asencor, Andoni I , Huynh, Trung , Tubati, Asritha , Haney, Michael S , Louine, Martineau , Cree, Bruce Ac , Hauser, Stephen L. , Seeley, William , Baranzini, Sergio E , Wells, James A , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth S , Gillum, Leslie , Zikherman, Julie , Anderson, Mark S , Yazdany, Jinoos , Smith, Bryan , Nath, Avindra , Suh, Gina A , Flanagan, E P , Green, Ari J , Green, Ralph , Gelfand, Jeffrey M , DeRisi, Joseph L , Pleasure, Samuel J , Wilson, Michael R , Pluvinage, John V , Bodansky, Aaron , Hinman, Samuel S. , McCann, Adrian , Cree, Bruce , Seeley, William W. , Yazdany, Jinoos , Suh, Gina A. , Flanagan, Eoin P. , Gelfand, Jeffrey M.

Mayo Clinic

Science Translational Medicine | June 26, 2024 | Volume: 16 | Issue: 753 | Pages: No page available

10.1126/scitranslmed.adl3758 | PMID 38924428 Get It

Vitamin B12 is critical for hematopoiesis and myelination. Deficiency can cause neurologic deficits including loss of coordination and cognitive decline. However, diagnosis relies on measurement of vitamin B12 in the blood, which may not accurately reflect the concentration in the brain. Using programmable phage display, we identified an autoantibody targeting the transcobalamin receptor (CD320) in a patient with progressive tremor, ataxia, and scanning speech. Anti-CD320 impaired cellular uptake of cobalamin (B12) in vitro by depleting its target from the cell surface. Despite a normal serum concentration, B12 was nearly undetectable in her cerebrospinal fluid (CSF). Immunosuppressive treatment and high-dose systemic B12 supplementation were associated with increased B12 in the CSF and clinical improvement. Optofluidic screening enabled isolation of a patient-derived monoclonal antibody that impaired B12 transport across an in vitro model of the blood-brain barrier (BBB). Autoantibodies targeting the same epitope of CD320 were identified in seven other patients with neurologic deficits of unknown etiology, 6% of healthy controls, and 21.4% of a cohort of patients with neuropsychiatric lupus. In 132 paired serum and CSF samples, detection of anti-CD320 in the blood predicted B12 deficiency in the brain. However, these individuals did not display any hematologic signs of B12 deficiency despite systemic CD320 impairment. Using a genome-wide CRISPR screen, we found that the low-density lipoprotein receptor serves as an alternative B12 uptake pathway in hematopoietic cells. These findings dissect the tissue specificity of B12 transport and elucidate an autoimmune neurologic condition that may be amenable to immunomodulatory treatment and nutritional supplementation.
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
French, Jena D. , Haugen, Bryan R. , Worden, Francis P. , Bowles, Daniel W. , Gianoukakis, Andrew G. , Konda, Bhavana , Dadu, Ramona , Sherman, Eric J. , McCue, Shaylene , Foster, Nathan R. , Farias, Ticiana D.J. , Norman, Paul J. , Wirth, Lori J. , Nikiforov, Yuri , Farias, Ticiana D J , Norman, Paul J , Wirth, Lori J , Bowles, Daniel W , Worden, Frank , Nikiforov, Yuri E.

Mayo Clinic

Clinical Cancer Research | June 26, 2024 | Volume: 30 | Issue: 17 | Pages: 3757-3767

10.1158/1078-0432.ccr-23-3417 | PMID 38922338 Get It

Abstract Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients. Patients and Methods: We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days. Results: In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1. Conclusions: Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy
Xiong, Wenzheng , May, Jeanne Tan May, Demmers, Tor, Ceronie, Bryan , Ramesh, Archana , McGinty, Ronan N. , Michael, Sophia , Torzillo, Emma, Anthony, Daniel C. , Irani, Sarosh R. , Irani, Sarosh R , Anthony, Daniel , Yeo, Tianrong , Sen, Arjune , Probert, Fay

Mayo Clinic

Annals of Clinical and Translational Neurology | June 22, 2024 | Volume: 11 | Issue: 7 | Pages: 1897-1908

10.1002/acn3.52112 | PMID 39012808 Get It

Abstract Objective Differentiating forms of autoimmune encephalitis (AE) from other causes of seizures helps expedite immunotherapies in AE patients and informs studies regarding their contrasting pathophysiology. We aimed to investigate whether and how Nuclear Magnetic Resonance (NMR)‐based metabolomics could differentiate AE from drug‐resistant epilepsy (DRE), and stratify AE subtypes. Methods This study recruited 238 patients: 162 with DRE and 76 AE, including 27 with contactin‐associated protein‐like 2 (CASPR2), 29 with leucine‐rich glioma inactivated 1 (LGI1) and 20 with N‐methyl‐ d ‐aspartate receptor (NMDAR) antibodies. Plasma samples across the groups were analyzed using NMR spectroscopy and compared with multivariate statistical techniques, such as orthogonal partial least squares discriminant analysis (OPLS‐DA). Results The OPLS‐DA model successfully distinguished AE from DRE patients with a high predictive accuracy of 87.0 ± 3.1% (87.9 ± 3.4% sensitivity and 86.3 ± 3.6% specificity). Further, pairwise OPLS‐DA models were able to stratify the three AE subtypes. Plasma metabolomic signatures of AE included decreased high‐density lipoprotein (HDL, −(C H 2 ) n −, –C H 3 ), phosphatidylcholine and albumin (lysyl moiety). AE subtype‐specific metabolomic signatures were also observed, with increased lactate in CASPR2, increased lactate, glucose, and decreased unsaturated fatty acids (UFA, –C H 2 CH=) in LGI1, and increased glycoprotein A (GlycA) in NMDAR‐antibody patients. Interpretation This study presents the first non‐antibody‐based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.
Migraine headache in patients with spontaneous coronary artery dissection: A report of the iSCAD Registry
Wells, Bryan J. , O’Duffy, Anne E, Grodzinsky, Anna , Gornik, Heather L. , Kadian‐Dodov, Daniella , Hess, Connie N. , Sanghavi, Monika , Tam, Lori , Orford, James L., Vitarello, Clara, Alkhalfan, Fahad , Leon, Katherine K, Naderi, Sahar , Kim, Esther S.H. , Chi, Gerald , Gornik, Heather L , Kadian-Dodov, Daniella , Henkin, Stanislav , Alkhalfan, Fahad , Wood, Malissa J. , Sumner, Jennifer A. , Taylor, Angela, Henkin, Stanislav , Wells, Gretchen , Lindley, Kathryn J , Kumbhani, Dharam J. , Gibson, C. Michael , Leon, Katherine K.

Mayo Clinic

Vascular Medicine | June 20, 2024 | Volume: 29 | Issue: 3 | Pages: 286-295

10.1177/1358863x241252444 | PMID 38898631 Get It

Introduction: Spontaneous coronary artery dissection (SCAD) is a nonatherosclerotic cause of myocardial infarction. Migraine headache has been reported to be common among patients with SCAD, but the degree of migraine-related disability has not been quantified. Methods: Clinical data and headache variables were obtained from the baseline assessment of the prospective, multicenter iSCAD Registry. Migraine-related disability was quantified using the self-reported Migraine Disability Assessment (MIDAS). Demographic, clinical, psychosocial, and medical characteristics from data entry forms were compared between patients with and without migraine. Results: Of the 773 patients with available data, 46% reported previous or current migraines. Those with migraines were more likely to be women (96.9% vs 90.3%, p = 0.0003). The presence of underlying carotid fibromuscular dysplasia was associated with migraine (35% vs 27%, p = 0.0175). There was not a significant association with carotid artery dissection and migraine. Current migraine frequency was less than monthly (58%), monthly (24%), weekly (16%), and daily (3%). Triptan use was reported in 32.5% of patients, and 17.5% used daily migraine prophylactic medications. Using the MIDAS to quantify disability related to migraine, 60.2% reported little or no disability, 14.4% mild, 12.7% moderate, and 12.7% severe. The mean MIDAS score was 9.9 (mild to moderate disability). Patients with SCAD had higher rates of depression and anxiety (28.2% vs 17.7% [ p = 0.0004] and 35.3% vs 26.7% [ p = 0.0099], respectively). Conclusions: Migraines are common, frequent, and a source of disability in patients with SCAD. The association between female sex, anxiety, and depression may provide some insight for potential treatment modalities.
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Weinstein, Gregory S., Mehra, Ranee , García, Joaquín J. , Kim, Seungwon , O’Malley, Bert W. , Özer, Enver , Koch, Wayne M. , Morris, Luc, Smith, Russell K., Karakla, Daniel W., Burtness, Barbara , Flamand, Yael , Quon, Harry , Gross, Neil D , Bell, R. Bryan , Patel, Mihir R , Lango, Miriam N. , Richmon, Jeremy D. , Holsinger, F. Christopher , Ferris, Robert L.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 6009-6009

10.1200/jco.2024.42.16_suppl.6009 Get It

6009 Background: E3311 is a phase II trial of TOS by credentialed surgeons with pathology-driven deintensified post-operative management in HPV+ OPC. Intermediate risk patients were randomized between standard and reduced dose radiation. We present mature outcome data, at median follow up of 52.4 months (m). Methods: Patients were eligible who had resectable cT1-2 stage III/IV AJCC7 p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (Arm A, N=38); those with clear margins, 2-4 + LN, or ENE ≤1mm were randomized to 50Gy (Arm B, N=100) or 60Gy (Arm C, N=108); those with involved margins, >4 + LN, or >1mm ENE received weekly cisplatin 40 mg/m2 and 60-66Gy (Arm D, N=113). Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared using a log-rank test, stratified by arm for comparisons of primary site and smoking history. Results: Among 359 evaluable patients, 54-m PFS and OS were 90.6% (90% CI: 87.2%, 93.1%) and 95.3% (90% CI: 93.0%, 96.9%). 54-m PFS by arm was: A 93.2% (90% CI: 79.6%, 97.8%); B 94.9% (90% CI: 89.7%, 97.5%); C 90.2% (90% CI: 82.7%, 94.6%) and D 85.5% (90% CI: 77.5%, 90.8%). 54-m OS by arm was: A 97.1% (90% CI: 85.7%, 99.4%); B 97.9% (90% CI: 93.5%, 99.3%), C 95.1% (90% CI: 90.1%, 97.6%) and D 92.5% (90% CI: 86.9%, 95.7%). Among patients in Arm A, 11 had N0 and 27 N1 stage. Median Arm A lymph node yield (LNY) was 29 (11 to 91 LN) and did not differ for patients with/without recurrence (p=0.83). All Arm A recurrences were in N1 patients: 1 at 18 m and 3 at > 40 m. No significant difference in PFS or OS was observed by prescribed radiation dose for intermediate risk patients (Arm B vs. C). Outcome did not differ by primary site of tonsil vs. other OPC (oOPC): 54-m PFS Tonsil 89.3% (90% CI: 84.9%, 92.5%) vs. oOPC 92.9% (90% CI: 87.0%, 96.2%), p=0.28, and 54-m OS Tonsil 94.6% (90% CI: 91.5%, 96.6%) vs oOPC 96.6% (90% CI: 92.4%, 98.5%), p=0.35. Smoking history also did not impact outcome. 54-m PFS was 89.9% (90% CI: 85.9%, 92.9%) for those with ≤10 pack-years (PY) tobacco exposure and 91.7% (90% CI: 83.9%, 95.9%) for those with >10 PY. Conclusions: TOS, neck dissection with deintensified risk-based post-operative management results in outstanding 54-m PFS and OS across all subsites of T1-2 p16+ OPC, irrespective of smoking history. Late recurrence is not increased when post-operative radiation is reduced from 60 to 50Gy for intermediate risk patients. Pathologic >1mm ENE (N=87), involved margin (N=12) or >4 involved LN (N=30) accurately identify patients at increased recurrence risk and outcomes were favorable among such patients. Among patients with favorable pathologic characteristics, a subset with N1 disease are at risk for late recurrence and further characterization of these patients is warranted. Clinical trial information: NCT01898494 .
Angle‐based minimally invasive glaucoma surgery in normal tension glaucoma: A systematic review and meta‐analysis
Oo, Hnin Hnin , Hong, Ashley Shuen Ying , Lim, Sheng Yang , Ang, Bryan C H

Mayo Clinic

Clinical & Experimental Ophthalmology | June 10, 2024 | Volume: 52 | Issue: 7 | Pages: 740-760

10.1111/ceo.14408 | PMID 38853535 Get It

AbstractBackgroundThis systematic review and meta‐analysis quantitatively examines the efficacy of angle‐based minimally invasive glaucoma surgery (MIGS) in normal tension glaucoma (NTG).MethodsA literature search was performed on Medline, Embase, PubMed, CINAHL and Cochrane Library from inception until 20 December 2022. Pilot, cohort, observational studies and randomised controlled trials including at least 5 subjects undergoing angle‐based MIGS (trabecular‐bypass devices, excisional trabeculotomy, goniotomy and ab‐interno canaloplasty) for NTG, with or without cataract surgery, were included. Meta‐analysis of continuous outcome using the meta routine in R version 2022.12.0+353 was performed to determine mean intraocular pressure (IOP) and anti‐glaucoma medication (AGM) reduction post‐operatively.ResultsOf the 846 studies initially identified, 15 studies with a pooled total of 367 eyes which underwent combined phacoemulsification and angle‐based MIGS were included for final meta‐analysis. Outcomes of the iStent were reported in 5 studies, iStent inject in 7 studies, Hydrus Microstent in 1 study, Kahook Dual Blade in 3 studies, and Trabectome in 2 studies. There was significant reduction in both IOP and AGM post‐operatively at 6 months (2.44 mmHg, 95%CI: 1.83–3.06; 1.21 AGM, 95%CI: 0.99–1.44), 12 months (2.28 mmHg, 95%CI: 1.71–2.84; 1.18 AGM, 95%CI: 0.90–1.47), 24 months (2.10 mmHg, 95%CI: 1.51–2.68; 1.26 AGM, 95%CI: 0.85–1.68) and 36 months (2.43 mmHg, 95%CI: 1.71–3.15, 0.87 AGM, 95%CI: 0.21–1.53) (all p < 0.05). Subgroup analysis on combined phacoemulsification‐iStent inject surgery demonstrated a reduction in both IOP (2.31 mmHg, 95%CI: 1.07–3.56, p < 0.001) and AGM (1.07 AGM, 95%CI: 0.86–1.29, p < 0.001) at 12 months post‐operatively.ConclusionsAngle‐based MIGS combined with phacoemulsification effectively reduces IOP and AGM in NTG eyes for up to 36 months after surgery.
Delays to Antibiotics in the Emergency Department and Risk of Mortality in Children With Sepsis
Lane, Roni D. , Richardson, Troy , Scott, Halden F. , Paul, Raina, Balamuth, Fran , Riggs, Ruth , Horvat, Christopher M. , Keeney, Grant E., Hueschen, Leslie A. , Lockwood, Justin M. , Gunnala, Vishal , McKee, Bryan, Patankar, Nikhil, Pinto, Venessa , Sebring, Amanda, Sharron, Matthew , Treseler, Jennifer, Wilkes, Jennifer J. , Workman, Jennifer K. , Eisenberg, Matthew A. , Huskins, W. Charles

Mayo Clinic

JAMA Network Open | June 5, 2024 | Volume: 7 | Issue: 6 | Pages: e2413955

10.1001/jamanetworkopen.2024.13955 | PMID 38837160 Get It

Importance Pediatric consensus guidelines recommend antibiotic administration within 1 hour for septic shock and within 3 hours for sepsis without shock. Limited studies exist identifying a specific time past which delays in antibiotic administration are associated with worse outcomes. Objective To determine a time point for antibiotic administration that is associated with increased risk of mortality among pediatric patients with sepsis. Design, Setting, and Participants This retrospective cohort study used data from 51 US children’s hospitals in the Improving Pediatric Sepsis Outcomes collaborative. Participants included patients aged 29 days to less than 18 years with sepsis recognized within 1 hour of emergency department arrival, from January 1, 2017, through December 31, 2021. Piecewise regression was used to identify the inflection point for sepsis-attributable 3-day mortality, and logistic regression was used to evaluate odds of sepsis-attributable mortality after adjustment for potential confounders. Data analysis was performed from March 2022 to February 2024. Exposure The number of minutes from emergency department arrival to antibiotic administration. Main Outcomes and Measures The primary outcome was sepsis-attributable 3-day mortality. Sepsis-attributable 30-day mortality was a secondary outcome. Results A total of 19 515 cases (median [IQR] age, 6 [2-12] years) were included. The median (IQR) time to antibiotic administration was 69 (47-116) minutes. The estimated time to antibiotic administration at which 3-day sepsis-attributable mortality increased was 330 minutes. Patients who received an antibiotic in less than 330 minutes (19 164 patients) had sepsis-attributable 3-day mortality of 0.5% (93 patients) and 30-day mortality of 0.9% (163 patients). Patients who received antibiotics at 330 minutes or later (351 patients) had 3-day sepsis-attributable mortality of 1.2% (4 patients), 30-day mortality of 2.0% (7 patients), and increased adjusted odds of mortality at both 3 days (odds ratio, 3.44; 95% CI, 1.20-9.93; P = .02) and 30 days (odds ratio, 3.63; 95% CI, 1.59-8.30; P = .002) compared with those who received antibiotics within 330 minutes. Conclusions and Relevance In this cohort of pediatric patients with sepsis, 3-day and 30-day sepsis-attributable mortality increased with delays in antibiotic administration 330 minutes or longer from emergency department arrival. These findings are consistent with the literature demonstrating increased pediatric sepsis mortality associated with antibiotic administration delay. To guide the balance of appropriate resource allocation with time for adequate diagnostic evaluation, further research is needed into whether there are subpopulations, such as those with shock or bacteremia, that may benefit from earlier antibiotics.
A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type
Webb, Lauren M. , Neth, Bryan J. , Carabenciov, Ivan D. , Ruff, Michael W. , Neth, Byran J. , Raghunathan, Aditya , Greipp, Patricia T. , Ida, Cristiane M.

Mayo Clinic

The Neurologist | May 27, 2024 | Volume: 29 | Issue: 4 | Pages: 254-258

10.1097/nrl.0000000000000564 | PMID 38797928 Get It

Introduction: Glioblastoma is a uniformly lethal primary central nervous system neoplasm. Despite the increased understanding of its pathophysiology and treatment advancements, median overall survival for patients with glioblastoma, IDH-wild type remains 14 to 21 months from diagnosis. Case Report: We present the case of a 48-year-old female who presented with a focal seizure and was found to have a right frontal lobe mass on the brain magnetic resonance imaging. She underwent gross total resection and received a histological diagnosis of glioblastoma. She received radiotherapy and 6 cycles of carmustine (BCNU). Seventeen months later, she developed left hemiparesis. Imaging was concerning for tumor progression, and she was treated with 1 cycle of mechlorethamine, vincristine (oncovin), procarbazine, and prednisone (MOPP). Subsequent surveillance imaging demonstrated a therapeutic response. Twenty-seven years after her glioblastoma diagnosis, she developed status epilepticus and died from respiratory failure. Neuropathology on autopsy demonstrated extensive treatment-related changes but no evidence of recurrent glioblastoma. Genomic testing performed over 30 years after her original diagnosis revealed a profile diagnostic of glioblastoma, IDH-wild type per 2021 World Health Organization criteria. Conclusions: This patient is one of the longest-known survivors of glioblastoma, IDH-wild type, with pathologic confirmation of glioblastoma at the time of her resection and no evidence of residual disease 26 years after her last treatment. She presented with multiple factors associated with long-term glioblastoma survivorship, including female sex, young age, high Karnofsky score, and multimodal therapy. This case shows that long-term survival after glioblastoma diagnosis is possible and likely mediated through a combination of individual, tumor, and treatment factors.
Experiences of Residents and Fellows at Mayo Clinic After the Rapid Implementation of Telemedicine During the COVID-19 Pandemic
Clapp, Adrianna D.M. , Punj, Mantavya , Farford, Bryan , TerKonda, Sarvam P. , Hattery, Wendy M., Leak, Michelle A. , Austin, Matthew K., Keith, Joshua J., Presutti, R. John , Farford, Bryan A , Clapp, Adrianna

Mayo Clinic

Journal of Medical Education and Curricular Development | May 23, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23821205241256259 | PMID 38799177 Get It

OBJECTIVE The COVID-19 pandemic led to many changes across medical organizations and graduate medical education programs nationwide including the rapid implementation of telemedicine as a modality for delivering health care. The purpose of this study was to investigate the telemedicine experiences of residents and fellows with their self-reported level of preparedness, impact on their education including precepting, skill development, and patient-physician relationships, and perceptions of telehealth platforms and curricula in the future. METHODS A total of 365 Mayo Clinic residents and fellows across three sites (Florida, Arizona, and Minnesota) were identified as trainees who conducted at least one telemedicine encounter from January 1, 2020 to June 30, 2020 and were sent an electronic survey by e-mail. RESULTS There was a total of 103 completed surveys across various specialties with 58.3% female respondents, 63.1% residents, 35.0% fellows and 77.7% of respondents who attended medical school in the United States. Most trainees reported having very little to no exposure to telemedicine in their medical careers before the pandemic. The majority were satisfied with their first telemedicine encounter and found precepting comparable to in-person visits. The trainees in this study had a favorable view with 98.1% believing telemedicine will play a more prevalent role in the future and most agreed this should be included in medical school and residency training. CONCLUSION Our survey found that after the implementation of telemedicine during the COVID-19 pandemic, the experiences of trainees at a multi-site academic center were overall positive. More research is needed on the perceptions of skill development (physical exam and history taking) during a telemedicine encounter and outlining an optimal telemedicine curriculum that can improve confidence in trainees.